Advanced Life Sciences Holdings’ Restanza promising against tularemia Advanced Life Sciences Holdings, Inc. , announced positive top-line outcomes from a pivotal today, nonhuman primate research of its novel, once-a-day, oral antibiotic Restanza against an inhaled lethal dosage of tularemia. A 14-day span of Restanza attained a 100 percent survival price at the dosages tested www.med-drugs.com . All of the ten animals in the study that received 16 mg/kg once-a-time of Restanza within a day after exposure to a lethal dosage of inhaled tularemia survived while only one of the ten pets that received placebo survived.
What takes 12 to 15 mere seconds for other scanners to full takes no more than a third of another for the 320-slice machine. Aquilion One can intermittently take pictures continuously or, allowing doctors to see the center pumping, or blood or medication functioning through the vascular system. Related StoriesLatest research on thyroid cancers to become highlighted at 15th International Thyroid CongressLow-dose occupational radiation exposure increases solid cancers riskResearchers report brand-new breakthrough in countering deadly ramifications of radiation exposure One of the most exciting reasons for having this technology is the real-time ability to image changing anatomy, stated Dr.